Microbot Medical (NASDAQ:MBOT) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Microbot Medical (NASDAQ:MBOT) from a hold rating to a sell rating in a report issued on Saturday morning.

MBOT has been the topic of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Microbot Medical in a report on Wednesday, October 15th. Zacks Research lowered Microbot Medical from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 21st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Microbot Medical in a report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $12.00.

Microbot Medical Stock Down 1.2%

NASDAQ MBOT opened at $2.39 on Friday. Microbot Medical has a 52-week low of $0.89 and a 52-week high of $4.67. The business’s 50-day moving average price is $3.32 and its 200 day moving average price is $2.84. The firm has a market cap of $160.51 million, a P/E ratio of -4.12 and a beta of 1.25.

Microbot Medical (NASDAQ:MBOT) last released its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). As a group, analysts anticipate that Microbot Medical will post -0.71 earnings per share for the current year.

Institutional Investors Weigh In On Microbot Medical

A number of hedge funds and other institutional investors have recently modified their holdings of MBOT. Virtu Financial LLC acquired a new stake in shares of Microbot Medical during the 1st quarter valued at approximately $42,000. Goldman Sachs Group Inc. acquired a new stake in shares of Microbot Medical during the 1st quarter valued at approximately $57,000. U.S. Capital Wealth Advisors LLC acquired a new stake in shares of Microbot Medical during the 2nd quarter valued at approximately $25,000. Beacon Capital Management LLC lifted its position in shares of Microbot Medical by 166.7% during the 2nd quarter. Beacon Capital Management LLC now owns 16,000 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 10,000 shares during the period. Finally, Lazari Capital Management Inc. acquired a new stake in shares of Microbot Medical during the 2nd quarter valued at approximately $54,000. 16.30% of the stock is currently owned by institutional investors and hedge funds.

About Microbot Medical

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.